Staff Members - Benha University
Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study
The Journal of Clinical Endocrinology & Metabolism • 2017
Publication Information
Authors
Gautam U Mehta Dale Ding Mohana Rao Patibandla Hideyuki Kano Nathaniel Sisterson Yan-Hua Su Michal Krsek Ahmed M Nabeel Amr El-Shehaby Khaled A Kareem Nuria Martinez-Moreno David Mathieu Brendan McShane Kevin Blas Douglas Kondziolka Inga Grill
Keywords
Not Available
Journal
The Journal of Clinical Endocrinology & Metabolism
Publisher
Endocrine Society
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Abstract
Context
Cushing disease (CD) due to adrenocorticotropic hormone–secreting pituitary tumors can be a management challenge.
Objective
To better understand the outcomes of stereotactic radiosurgery (SRS) for CD and define its role in management.
Design
International, multicenter, retrospective cohort analysis.
Setting
Ten medical centers participating in the International Gamma Knife Research Foundation.
Patients
Patients with CD with >6 months endocrine follow-up.
Intervention
SRS using Gamma Knife radiosurgery.
Main Outcome Measures
The primary outcome was control of hypercortisolism (defined as normalization of free urinary cortisol). Radiologic response and adverse radiation effects (AREs) were recorded.
Results
In total, 278 patients met inclusion criteria, with a mean follow-up of 5.6 years (0.5 to 20.5 years). Twenty-two patients received SRS as a primary treatment of CD. Mean margin dose was 23.7 Gy. Cumulative initial control of hypercortisolism was 80% at 10 years. Mean time to cortisol normalization was 14.5 months. Recurrences occurred in 18% with initial cortisol normalization. Overall, the rate of durable control of hypercortisolism was 64% at 10 years and 68% among patients who received SRS as a primary treatment. AREs included hypopituitarism (25%) and cranial neuropathy (3%). Visual deficits were related to treatment of tumor within the suprasellar cistern (P = 0.01), whereas both visual (P < 0.0001) and nonvisual cranial neuropathy (P = 0.02) were related to prior pituitary irradiation.
Conclusions
SRS for CD is well tolerated and frequently results in control of hypercortisolism. However, recurrences can occur. SRS should be considered for patients with persistent hypercortisolism after pituitary surgery and as a primary treatment in those unfit for surgery. Long-term endocrine follow-up is essential after SRS.
Context
Cushing disease (CD) due to adrenocorticotropic hormone–secreting pituitary tumors can be a management challenge.
Objective
To better understand the outcomes of stereotactic radiosurgery (SRS) for CD and define its role in management.
Design
International, multicenter, retrospective cohort analysis.
Setting
Ten medical centers participating in the International Gamma Knife Research Foundation.
Patients
Patients with CD with >6 months endocrine follow-up.
Intervention
SRS using Gamma Knife radiosurgery.
Main Outcome Measures
The primary outcome was control of hypercortisolism (defined as normalization of free urinary cortisol). Radiologic response and adverse radiation effects (AREs) were recorded.
Results
In total, 278 patients met inclusion criteria, with a mean follow-up of 5.6 years (0.5 to 20.5 years). Twenty-two patients received SRS as a primary treatment of CD. Mean margin dose was 23.7 Gy. Cumulative initial control of hypercortisolism was 80% at 10 years. Mean time to cortisol normalization was 14.5 months. Recurrences occurred in 18% with initial cortisol normalization. Overall, the rate of durable control of hypercortisolism was 64% at 10 years and 68% among patients who received SRS as a primary treatment. AREs included hypopituitarism (25%) and cranial neuropathy (3%). Visual deficits were related to treatment of tumor within the suprasellar cistern (P = 0.01), whereas both visual (P < 0.0001) and nonvisual cranial neuropathy (P = 0.02) were related to prior pituitary irradiation.
Conclusions
SRS for CD is well tolerated and frequently results in control of hypercortisolism. However, recurrences can occur. SRS should be considered for patients with persistent hypercortisolism after pituitary surgery and as a primary treatment in those unfit for surgery. Long-term endocrine follow-up is essential after SRS.